Next-Generation Breast Cancer Diagnostic and Screening Market - A Global Market and Regional Analysis: Focus on Technology, Cancer Sub-Type, Biomarker, Offering, End User, and Country Analysis - Analysis and Forecast, 2023-2032
Global Next-Generation Breast Cancer Diagnostic and Screening Market: Industry Overview
The global next-generation breast cancer diagnostic and screening market was valued at $3,137.4 million in 2022 and is anticipated to reach $9,880.1 million by 2032, witnessing a CAGR of 12.57% during the forecast period 2023-2032. The growth in the global next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases globally, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.
Market Lifecycle Stage
The next-generation breast cancer diagnostic and screening market is in the developing phase. Technological advancements in the development of next-generation breast cancer diagnostics and the growing scope for molecular breast cancer diagnosis techniques in emerging countries can be some of the major opportunities in the global next-generation breast cancer diagnostic and screening market. Furthermore, some of the key trends going on in the market are the implementation of liquid biopsy for breast cancer diagnosis and the complete automation of next-generation techniques.
Impact of COVID-19
COVID-19 had a significant impact on the global next-generation breast cancer diagnostic and screening market. There was a significant shift observed toward research activities for treating and diagnosing COVID-19, which resulted in a halt in research activities for next-generation breast cancer diagnostic and screening. Moreover, the market players witnessed a loss in 2020 due to COVID-19 restrictions and prevention actions such as a reduction in supply chain and sales.
However, since the situations are now almost back to normal, the next-generation breast cancer diagnostic and screening market is expected to overcome all the impact of COVID-19 during the forecast period 2023-2032.
Market Segmentation:
Segmentation 1: by Technology
- Real-Time PCR
- Immunohistochemistry (IHC)
- Next-Generation Sequencing (NGS)
- Fluorescence In-Situ Hybridization (FISH)
- Others
Segmentation 2: by Biomarker
- BRCA1/2
- ER/PR Receptors
- HER-2
- Others
Segmentation 3: by Cancer Sub-Type
- Luminal A
- Luminal B
- Triple Negative/Basal Like
- Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched
Segmentation 4: by Offering
- Products
- Services
Segmentation 5: by End User
- Hospitals and Clinics
- Diagnostic Centers and Reference Labs
- Academic and Research Institutes
Segmentation 6: by Region
- North America - U.S., Canada
- Europe - Germany, France, U.K., Italy, Spain, and Rest-of-Europe
- Asia-Pacific - Japan, China, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
- Latin America - Brazil, Mexico, and Rest-of-Latin America
- Rest-of-the-World
Recent Developments in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- In April 2023, Syantra Inc., a Canada-based company, received CE mark approval for its Syantra DX breast cancer test.
- In March 2023, NeoGenomics, Inc. launched its RaDaR assay, which is a liquid biopsy test for minimal residual disease (MRD).
- In February 2023, HALO Diagnostics launched its new HALO pathway for early breast cancer detection.
- In January 2023, Agilent Technologies, Inc. acquired Avida Biomed, a company that develops high-performance NGS target enrichment workflows for cancer research.
- In October 2022, Lucence Diagnostics Pte Ltd entered into a distribution partnership with Omnigen, under which Omnigen would distribute Lucence Diagnostics Pte Ltd’s LiquidHALLMARK assay in Turkey.
- In March 2022, Myriad Genetics, Inc. received the U.S. FDA approval for its BRACanalysis CDx for being used as a companion diagnostic test and for the identification of breast cancer patients who may benefit from Lynparza in early breast cancer stages.
- In February 2022, Laboratory Corporation of America Holdings acquired Personal Genome Diagnostics Inc., a company that deals in cancer genomics and provides an assortment of comprehensive liquid biopsy and tissue-based products.
- In January 2022, Agendia Inc. entered into a partnership with Illumina Inc. to expand genomic testing for breast cancer care.
- In December 2021, Exai Bio, Inc. raised funding of $67.5 million as a part of its Series A funding round. The funding was in order to bring advancement in the next-generation RNA-based liquid biopsy platform of the company, which is indicated for early detection of cancer.
- In June 2021, Veracyte, Inc. acquired HalioDx for an amount of $318 million to expand its portfolio in cancer in-vitro diagnostics.
- In May 2021, Hologic, Inc. acquired Biotheranostics, Inc., a company that provides molecular diagnostic tests for breast and metastatic cancers.
- In November 2020, Agilent Technologies, Inc. received U.S. FDA approval for its PD-L1 IHC 22C3 pharmDx for triple-negative breast cancer.
Following are the drivers for the global next-generation breast cancer diagnostic and screening market:
- Increasing Prevalence of Breast Cancer Globally
- Increased Awareness Regarding Early Diagnosis of Breast Cancer
- Growing Focus on Breast Cancer Biomarkers for Effective Screening, Prognosis, and Personalized Treatment
- Increasing Partnerships and Collaborations amongst Market Players
- High Cost of Tests and Requirement of High Capital Investment for Testing Set-Up
- Occurrence of False Positive and False Negative Results
Product/Innovation Strategy: The technology segment helps the reader understand the different types of technologies being used in next-generation breast cancer diagnosis and screening. Moreover, the study provides the reader with a detailed understanding of the next-generation breast cancer diagnostic and screening market based on biomarkers (BRCA1/2, ER/PR receptors, HER-2, and others), cancer sub-type (luminal A, luminal B, triple negative/basal-like, and HER-2 enriched), and offerings (products and services).
Growth/Marketing Strategy: The global next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the global next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.
Competitive Strategy: Key players in the global next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, and market penetration.
Key Companies Profiled
- Abbott Laboratories
- Agendia Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- BGI Genomics Co., Ltd.
- CENTOGENE N.V.
- Danaher Corporation
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- Thermo Fisher Scientific Inc.
- Lucence Diagnostics Pte Ltd
- Myriad Genetics, Inc.
- Natera, Inc.
*PDF email from publisher allows for 1-3 users, with permission to print*
- 1 Oncology Molecular Diagnostic Market
- 1.1 Overview
- 1.2 Cancer Type
- 1.3 Technology
- 1.4 Market Dynamics
- 1.5 Regulatory-Approved Products
- 2 Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 2.1 Global Market Outlook
- 2.1.1 Product Definition
- 2.1.2 Definition by Technologies Involved
- 2.1.2.1 Real-Time Polymerase Chain Reaction (RT-PCR)
- 2.1.2.2 Fluorescence In-Situ Hybridization (FISH)
- 2.1.2.3 Next-Generation Sequencing
- 2.1.2.4 Immunohistochemistry (IHC)
- 2.1.3 Inclusion and Exclusion
- 2.1.4 Overview
- 2.1.4.1 Global Market Size and Growth Potential, $Million, 2022-2032
- 3 Industry Outlook
- 3.1 Key Trends
- 3.1.1 Liquid Biopsy for Breast Cancer Diagnosis
- 3.1.2 Complete Automation of Next-Generation Techniques
- 3.2 Regulatory Framework
- 3.2.1 Regulatory Framework in the U.S.
- 3.2.1.1 FDA Regulation
- 3.2.1.2 CMS Regulations (Reimbursement Scenario)
- 3.2.2 Regulatory Framework in Europe
- 3.2.3 Regulatory Framework in Asia-Pacific
- 3.2.3.1 China
- 3.2.3.2 Japan
- 3.3 Regulatory-Approved Products
- 3.4 Clinical Trials
- 3.5 Breast Cancer Incidence Growth Rates (by Country)
- 3.6 Advantages and Limitations of Different Techniques
- 3.7 Pricing
- 4 Impact of COVID-19 on Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 4.1 Impact of COVID-19 on Next-Generation Breast Cancer Diagnostic and Screening Overall Market
- 4.2 Pre-COVID-19 Phase
- 4.3 During-COVID-19 Phase
- 4.4 Post-COVID-19 Phase
- 5 Business Dynamics
- 5.1 Impact Analysis
- 5.2 Business Drivers
- 5.2.1 Increasing Prevalence of Breast Cancer Globally
- 5.2.2 Increased Awareness Regarding Early Diagnosis of Breast Cancer
- 5.2.3 Growing Focus on Breast Cancer Biomarkers for Effective Screening, Prognosis, and Personalized Treatment
- 5.2.4 Increasing Partnerships and Collaborations amongst Market Players
- 5.3 Business Restraints
- 5.3.1 High Cost of Tests and Requirement of High Capital Investment for Testing Set-Up
- 5.3.2 Occurrence of False Positive and False Negative Results
- 5.4 Business Opportunities
- 5.4.1 Technological Advancements in the Development of Next-Generation Breast Cancer Diagnostics
- 5.4.2 Growing Scope for Molecular Breast Cancer Diagnosis Techniques in Emerging Countries
- 6 Competitive Landscape
- 6.1 Overview
- 6.2 Key Strategies and Developments
- 6.2.1 Partnerships, Alliances, and Business Expansions
- 6.2.2 Regulatory and Legal Activities
- 6.2.3 Mergers and Acquisitions
- 6.2.4 New Offerings
- 6.2.5 Funding Activities
- 6.3 Market Share Analysis (by Company), 2022
- 6.4 Growth-Share Analysis (By Company), 2022
- 7 Global Next Generation Breast Cancer Diagnostic and Screening Market, By Technology
- 7.1 Overview
- 7.2 Growth-Share Matrix
- 7.3 Real-Time PCR (RT-PCR)
- 7.4 Immunohistochemistry (IHC)
- 7.5 Next-Generation Sequencing
- 7.6 Fluorescence In-Situ Hybridization (FISH)
- 7.7 Others
- 8 Global Next Generation Breast Cancer Diagnostic and Screening Market, by Biomarker
- 8.1 Overview
- 8.2 Growth-Share Matrix
- 8.3 BRCA1/2
- 8.4 ER/PR Receptors
- 8.5 Human Epidermal Growth Factor-2 (HER-2)
- 8.6 Others
- 9 Global Next Generation Breast Cancer Diagnostic and Screening Market, by Cancer Sub-Type
- 9.1 Overview
- 9.2 Growth-Share Matrix
- 9.3 Luminal A
- 9.4 Luminal B
- 9.5 Triple Negative/ Basal-Like
- 9.6 Human Epidermal Growth Factor-2 (HER-2) Enriched
- 10 Global Next Generation Breast Cancer Diagnostic and Screening Market, by Offering
- 10.1 Overview
- 10.2 Growth-Share Matrix
- 10.3 Products
- 10.4 Services
- 11 Global Next Generation Breast Cancer Diagnostics and Screening Market, by End User
- 11.1 Overview
- 11.2 Growth-Share Matrix
- 11.3 Hospitals and Clinics
- 11.4 Academic and Research Institutes
- 11.5 Diagnostic Centers and Reference Labs
- 12 Regions
- 12.1 North America
- 12.1.1 Key Findings
- 12.1.2 Market Dynamics
- 12.1.2.1 Impact Analysis
- 12.1.3 Market Sizing and Forecast
- 12.1.3.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
- 12.1.3.1.1 U.S.
- 12.1.3.1.1.1 Market Dynamics
- 12.1.3.1.1.2 Market Sizing and Forecast
- 12.1.3.1.2 Canada
- 12.1.3.1.2.1 Market Dynamics
- 12.1.3.1.2.2 Market Sizing and Forecast
- 12.2 Europe
- 12.2.1 Key Findings
- 12.2.2 Market Dynamics
- 12.2.2.1 Impact Analysis
- 12.2.3 Market Sizing and Forecast
- 12.2.3.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
- 12.2.3.1.1 Germany
- 12.2.3.1.1.1 Market Dynamics
- 12.2.3.1.1.2 Market Sizing and Forecast
- 12.2.3.1.2 France
- 12.2.3.1.2.1 Market Dynamics
- 12.2.3.1.2.2 Market Sizing and Forecast
- 12.2.3.1.3 U.K.
- 12.2.3.1.3.1 Market Dynamics
- 12.2.3.1.3.2 Market Sizing and Forecast
- 12.2.3.1.4 Italy
- 12.2.3.1.4.1 Market Dynamics
- 12.2.3.1.4.2 Market Sizing and Forecast
- 12.2.3.1.5 Spain
- 12.2.3.1.5.1 Market Dynamics
- 12.2.3.1.5.2 Market Sizing and Forecast
- 12.2.3.1.6 Rest-of-Europe
- 12.2.3.1.6.1 Market Dynamics
- 12.2.3.1.6.2 Market Sizing and Forecast
- 12.3 Asia-Pacific
- 12.3.1 Key Findings
- 12.3.2 Market Dynamics
- 12.3.2.1 Impact Analysis
- 12.3.3 Market Sizing and Forecast
- 12.3.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
- 12.3.3.1.1 China
- 12.3.3.1.1.1 Market Dynamics
- 12.3.3.1.1.2 Market Sizing and Forecast
- 12.3.3.1.2 Japan
- 12.3.3.1.2.1 Market Dynamics
- 12.3.3.1.2.2 Market Sizing and Forecast
- 12.3.3.1.3 India
- 12.3.3.1.3.1 Market Dynamics
- 12.3.3.1.3.2 Market Sizing and Forecast
- 12.3.3.1.4 Australia
- 12.3.3.1.4.1 Market Dynamics
- 12.3.3.1.4.2 Market Sizing and Forecast
- 12.3.3.1.5 South Korea
- 12.3.3.1.5.1 Market Dynamics
- 12.3.3.1.5.2 Market Sizing and Forecast
- 12.3.3.1.6 Singapore
- 12.3.3.1.6.1 Market Dynamics
- 12.3.3.1.6.2 Market Sizing and Forecast
- 12.3.3.1.7 Rest-of-Asia-Pacific
- 12.3.3.1.7.1 Market Dynamics
- 12.3.3.1.7.2 Market Sizing and Forecast
- 12.4 Latin America
- 12.4.1 Key Findings
- 12.4.2 Market Dynamics
- 12.4.2.1 Impact Analysis
- 12.4.3 Market Sizing and Forecast
- 12.4.3.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
- 12.4.3.1.1 Mexico
- 12.4.3.1.1.1 Market Dynamics
- 12.4.3.1.1.2 Market Sizing and Forecast
- 12.4.3.1.2 Brazil
- 12.4.3.1.2.1 Market Dynamics
- 12.4.3.1.2.2 Market Sizing and Forecast
- 12.4.3.1.3 Rest-of-Latin America
- 12.4.3.1.3.1 Market Dynamics
- 12.4.3.1.3.2 Market Sizing and Forecast
- 12.5 Rest-of-the-World
- 12.5.1 Key Findings
- 12.5.2 Market Dynamics
- 12.5.2.1 Impact Analysis
- 12.5.3 Market Sizing and Forecast
- 13 Markets - Competitive Benchmarking
- 13.1 Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
- 13.2 Company Profiles
- 13.2.1 Abbott Laboratories
- 13.2.1.1 Company Overview
- 13.2.1.2 Role of Abbott Laboratories in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.1.3 Financials
- 13.2.1.4 Analyst Perception
- 13.2.2 Agendia Inc.
- 13.2.2.1 Company Overview
- 13.2.2.2 Role of Agendia Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.2.3 Recent Developments
- 13.2.2.4 Analyst Perception
- 13.2.3 Agilent Technologies, Inc.
- 13.2.3.1 Company Overview
- 13.2.3.2 Role of Agilent Technologies, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.3.3 Financials
- 13.2.3.4 Recent Developments
- 13.2.3.5 Analyst Perception
- 13.2.4 Bio-Rad Laboratories, Inc.
- 13.2.4.1 Company Overview
- 13.2.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.4.3 Financials
- 13.2.4.4 Analyst Perception
- 13.2.5 BGI Genomics Co., Ltd.
- 13.2.5.1 Company Overview
- 13.2.5.2 Role of BGI Genomics Co., Ltd. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.5.3 Financials
- 13.2.5.4 Recent Developments
- 13.2.5.5 Analyst Perception
- 13.2.6 CENTOGENE N.V.
- 13.2.6.1 Company Overview
- 13.2.6.2 Role of CENTOGENE N.V. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.6.3 Financials
- 13.2.6.4 Recent Developments
- 13.2.6.5 Analyst Perception
- 13.2.7 Danaher Corporation
- 13.2.7.1 Company Overview
- 13.2.7.2 Role of Danaher Corporation in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.7.3 Financials
- 13.2.7.4 Analyst Perception
- 13.2.8 Exact Sciences Corporation
- 13.2.8.1 Company Overview
- 13.2.8.2 Role of Exact Sciences Corporation in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.8.3 Financials
- 13.2.8.4 Recent Developments
- 13.2.8.5 Analyst Perception
- 13.2.9 F. Hoffmann-La Roche Ltd.
- 13.2.9.1 Company Overview
- 13.2.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.9.3 Financials
- 13.2.9.4 Recent Developments
- 13.2.9.5 Analyst Perception
- 13.2.10 Illumina, Inc.
- 13.2.10.1 Company Overview
- 13.2.10.2 Role of Illumina, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.10.3 Financials
- 13.2.10.4 Recent Developments
- 13.2.10.5 Analyst Perception
- 13.2.11 Laboratory Corporation of America Holdings
- 13.2.11.1 Company Overview
- 13.2.11.2 Role of Laboratory Corporation of America Holdings in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.11.3 Financials
- 13.2.11.4 Recent Developments
- 13.2.11.5 Analyst Perception
- 13.2.12 Thermo Fisher Scientific Inc.
- 13.2.12.1 Company Overview
- 13.2.12.2 Role of Thermo Fisher Scientific Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.12.3 Financials
- 13.2.12.4 Recent Developments
- 13.2.12.5 Analyst Perception
- 13.2.13 Lucence Diagnostics Pte Ltd
- 13.2.13.1 Company Overview
- 13.2.13.2 Role of Lucence Diagnostics Pte Ltd in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.13.3 Recent Developments
- 13.2.13.4 Analyst Perception
- 13.2.14 Myriad Genetics, Inc.
- 13.2.14.1 Company Overview
- 13.2.14.2 Role of Myriad Genetics, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.14.3 Financials
- 13.2.14.4 Recent Developments
- 13.2.14.5 Analyst Perception
- 13.2.15 Natera, Inc.
- 13.2.15.1 Company Overview
- 13.2.15.2 Role of Natera, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
- 13.2.15.3 Financials
- 13.2.15.4 Recent Developments
- 13.2.15.5 Analyst Perception
- List of Figures
- Figure 1: Worldwide Breast Cancer Statistics (by Region), 2020
- Figure 2: Global Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 3: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Technology), $Million, 2022 and 2032
- Figure 4: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Biomarker), $Million, 2022 and 2032
- Figure 5: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Sub-Type), $Million, 2022 and 2032
- Figure 6: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Offering), $Million, 2022 and 2032
- Figure 7: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by End User), $Million, 2022 and 2032
- Figure 8: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), $Million, 2022 and 2032
- Figure 9: Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Figure 10: Next-Generation Breast Cancer Diagnostic and Screening Market, Key Development Analysis, January 2019-April 2023
- Figure 11: Global Next-Generation Breast Cancer Diagnostic and Screening Market Segmentation
- Figure 12: Global Next-Generation Breast Cancer Diagnostic and Screening Market: Research Methodology
- Figure 13: Primary Research Methodology
- Figure 14: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 15: Top-Down Approach (Segment-Wise Analysis)
- Figure 16: Oncology Molecular Diagnostic Market, Solid Tumor, $Million, 2022 and 2032
- Figure 17: Oncology Molecular Diagnostic Market, Hematological Malignancy, $Million, 2022 and 2032
- Figure 18: Oncology Molecular Diagnostic Market, Market Dynamics
- Figure 19: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Size and Growth Potential, $Million, 2022-2032
- Figure 20: Global Market Size and Growth Potential (by Region), $Million, 2022-2032
- Figure 21: FDA Guidelines for CDx Approval
- Figure 22: Criteria for CMS Coverage/Reimbursement
- Figure 23: Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
- Figure 24: Breast Cancer Incidence Growth Rates (by Country), 2020 and 2040
- Figure 25: Advantages and Limitations of Different Techniques in the Next-Generation Breast Cancer Diagnostic and Screening Market
- Figure 26: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Figure 27: Estimated Number of Global Incidence and Mortality of Breast Cancer in Females, 2020, 2030, and 2040
- Figure 28: Breast-Cancer Death Rates with Early Detection and/or Multimodality Treatment
- Figure 29: Share of Key Developments and Strategies, January 2019-April 2023
- Figure 30: Partnerships, Alliances, and Business Expansions (by Company), January 2019-April 2023
- Figure 31: Regulatory and Legal Activities (by Company), January 2019-April 2023
- Figure 32: Mergers and Acquisitions (by Company), January 2019-April 2023
- Figure 33: New Offerings (by Company), January 2019-April 2023
- Figure 34: Funding Activities (by Company), January 2019-April 2023
- Figure 35: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Company Revenue Share Analysis, $Million, 2022
- Figure 36: Growth-Share Analysis for Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Company), 2022
- Figure 37: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Technology)
- Figure 38: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Technology), $Million, 2023-2032
- Figure 39: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Growth-Share Matrix (by Technology), 2022-2032
- Figure 40: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Real-Time PCR), $Million, 2022-2032
- Figure 41: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Immunohistochemistry), $Million, 2022-2032
- Figure 42: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Next-Generation Sequencing), $Million, 2022-2032
- Figure 43: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Fluorescence In-Situ Hybridization), $Million, 2022-2032
- Figure 44: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Others), $Million, 2022-2032
- Figure 45: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on Other Techniques
- Figure 46: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Biomarker)
- Figure 47: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Biomarker), $Million, 2023-2032
- Figure 48: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Growth-Share Matrix (by Biomarker), 2022-2032
- Figure 49: Global Next-Generation Breast Cancer Diagnostic and Screening Market (BRCA1/2), $Million, 2022-2032
- Figure 50: Global Next-Generation Breast Cancer Diagnostic and Screening Market (ER/PR Receptors), $Million, 2022-2032
- Figure 51: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Human Epidermal Growth Factor-2), $Million, 2022-2032
- Figure 52: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Others), $Million, 2022-2032
- Figure 53: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Sub-Type)
- Figure 54: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Cancer Sub-Type), $Million, 2023-2032
- Figure 55: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Growth-Share Matrix (by Cancer Sub-Type), 2022-2032
- Figure 56: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Luminal A), $Million, 2022-2032
- Figure 57: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Luminal B), $Million, 2022-2032
- Figure 58: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Triple-Negative/Basal-Like), $Million, 2022-2032
- Figure 59: Global Next-Generation Breast Cancer Diagnostic and Screening Market (HER-2 Enriched), $Million, 2022-2032
- Figure 60: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Offering)
- Figure 61: Global Next-Generation Breast Cancer Diagnostic and Screening Market Opportunity (by Offering), $Million, 2023-2032
- Figure 62: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Growth-Share Matrix (by Offering), 2022-2032
- Figure 63: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Products), $Million, 2022-2032
- Figure 64: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Services), $Million, 2022-2032
- Figure 65: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by End User)
- Figure 66: Global Next-Generation Breast Cancer Diagnostic and Screening Market Opportunity (by End User), $Million, 2023-2032
- Figure 67: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Growth-Share Matrix (by End User), 2022-2032
- Figure 68: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Hospitals and Clinics), $Million, 2022-2032
- Figure 69: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Academic and Research Institutes), $Million, 2022-2032
- Figure 70: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Diagnostic Centers and Reference Labs), $Million, 2022-2032
- Figure 71: Global Next-Generation Breast Cancer Diagnostic and Screening Market Share (by Region), 2022-2032
- Figure 72: North America Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
- Figure 73: North America Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 74: North America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
- Figure 75: U.S. Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 76: Canada Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 77: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
- Figure 78: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 79: Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
- Figure 80: Germany Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 81: France Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 82: U.K. Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 83: Italy Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 84: Spain Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 85: Rest-of-Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 86: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
- Figure 87: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 88: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
- Figure 89: China Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 90: Japan Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 91: India Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 92: Australia Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 93: South Korea Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 94: Singapore Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 95: Rest-of-Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 96: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
- Figure 97: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 98: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
- Figure 99: Mexico Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 100: Brazil Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 101: Rest-of-Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 102: Rest-of-the-World Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 103: Abbott Laboratories: Product Portfolio
- Figure 104: Abbott Laboratories: Overall Financials, $Million, 2020-2022
- Figure 105: Abbott Laboratories: Net Revenue (by Segment), $Million, 2020-2022
- Figure 106: Abbott Laboratories: Net Revenue (by Region), $Million, 2020-2022
- Figure 107: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
- Figure 108: Agendia Inc.: Product Portfolio
- Figure 109: Agilent Technologies, Inc.: Product Portfolio
- Figure 110: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
- Figure 111: Agilent Technologies, Inc.: Net Revenue (by Segment), $Million, 2020-2022
- Figure 112: Agilent Technologies, Inc.: Net Revenue (by Region), $Million, 2020-2022
- Figure 113: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 114: Bio-Rad Laboratories, Inc.: Product Portfolio
- Figure 115: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
- Figure 116: Bio-Rad Laboratories, Inc.: Net Revenue (by Segment), $Million, 2020-2022
- Figure 117: Bio-Rad Laboratories, Inc.: Net Revenue (by Region), $Million, 2020-2022
- Figure 118: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 119: BGI Genomics Co., Ltd. Product Portfolio
- Figure 120: BGI Genomics Co., Ltd.: Overall Financials, $Million, 2020-2022
- Figure 121: CENTOGENE N.V.: Product Portfolio
- Figure 122: CENTOGENE N.V.: Overall Financials, $Million, 2019-2021
- Figure 123: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2019-2021
- Figure 124: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2019-2021
- Figure 125: CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021
- Figure 126: Danaher Corporation: Product Portfolio
- Figure 127: Danaher Corporation: Overall Financials, $Million, 2020-2022
- Figure 128: Danaher Corporation: Net Revenue (by Segment), $Million, 2022
- Figure 129: Danaher Corporation: Net Revenue (by Segment), $Million, 2019 and 2020
- Figure 130: Danaher Corporation: Net Revenue (by Region), $Million, 2020-2022
- Figure 131: Danaher Corporation: R&D Expenditure, $Million, 2020-2022
- Figure 132: Exact Sciences Corporation: Product Portfolio
- Figure 133: Exact Sciences Corporation: Overall Financials, $Million, 2020-2022
- Figure 134: Exact Sciences Corporation: Net Revenue (by Segment), $Million, 2020-2022
- Figure 135: Exact Sciences Corporation: Net Revenue (by Region), $Million, 2020-2022
- Figure 136: Exact Sciences Corporation: R&D Expenditure, $Million, 2020-2022
- Figure 137: F. Hoffmann-La Roche Ltd.: Product Portfolio
- Figure 138: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2020-2022
- Figure 139: F. Hoffmann-La Roche Ltd.: Net Revenue (by Segment), $Million, 2020-2022
- Figure 140: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2020-2022
- Figure 141: Illumina, Inc.: Product Portfolio
- Figure 142: Illumina, Inc.: Overall Financials, $Million, 2020-2022
- Figure 143: Illumina, Inc.: Net Revenue (by Segment), $Million, 2020-2022
- Figure 144: Illumina, Inc.: Net Revenue (by Region), $Million, 2020-2022
- Figure 145: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 146: Laboratory Corporation of America Holdings: Product Portfolio
- Figure 147: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2020-2022
- Figure 148: Laboratory Corporation of America Holdings: Net Revenue (by Segment), $Million, 2020-2022
- Figure 149: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 150: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
- Figure 151: Thermo Fisher Scientific Inc.: Net Revenue (by Segment), $Million, 2020-2022
- Figure 152: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Million, 2020-2022
- Figure 153: Lucence Diagnostics Pte Ltd: Product Portfolio
- Figure 154: Myriad Genetic, Inc.: Product Portfolio
- Figure 155: Myriad Genetic, Inc.: Overall Financials, $Million, 2020-2022
- Figure 156: Myriad Genetic, Inc.: Net Revenue (by Segment), $Million, 2021-2022
- Figure 157: Myriad Genetic, Inc.: Net Revenue (by Segment), $Million, 2020
- Figure 158: Myriad Genetic, Inc.: Net Revenue (by Region), $Million, 2020-2022
- Figure 159: Myriad Genetic, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 160: Natera, Inc.: Product Portfolio
- Figure 161: Natera, Inc.: Overall Financials, $Million, 2020-2022
- Figure 162: Natera, Inc.: Net Revenue (by Region), $Million, 2020-2022
- Figure 163: Natera, Inc.: R&D Expenditure, $Million, 2020-2022
- List of Tables
- Table 1: Key Questions Answered in the Report
- Table 2: Some of the Regulatory-Approved Oncology Molecular Diagnostic Products/Services for Different Types of Solid Tumors
- Table 3: Some of the Regulatory-Approved Next-Generation Breast Cancer Diagnostic and Screening Products/Tests
- Table 4: Global Next-Generation Breast Cancer Diagnostic and Screening, Clinical Trials
- Table 5: Pricing of Some Products/Services for Next-Generation Breast Cancer Diagnostic and Screening
- Table 6: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products Offered Based on Real-Time PCR Technique
- Table 7: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on Immunohistochemistry (IHC) Technique
- Table 8: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on Next-Generation Sequencing (NGS) Technique
- Table 9: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on FISH Technique
- Table 10: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on BRCA Biomarker
- Table 11: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on ER/PR Receptors Biomarker
- Table 12: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on HER-2 Biomarker
- Table 13: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on Other Biomarkers
- Table 14: North America Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Table 15: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Table 16: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Table 17: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Table 18: Rest-of-the-World Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Table 19: Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
- Table 20: Agendia Inc.: Key Services and Features
- Table 21: BGI Genomics Co. Ltd.: Key Products and Features
- Table 22: CENTOGENE N.V.: Key Services and Features
- Table 23: Danaher Corporation: Key Products and Features
- Table 24: Exact Sciences Corporation: Key Services and Features
- Table 25: F. Hoffmann-La Roche Ltd.: Key Products and Features
- Table 26: Illumina, Inc.: Key Products and Features
- Table 27: Laboratory Corporation of America Holdings: Key Products and Features
- Table 28: Thermo Fisher Scientific Inc.: Key Products and Features
- Table 29: Lucence Diagnostics Pte Ltd: Key Services and Features
- Table 30: Myriad Genetics, Inc.: Key Services and Features
- Table 31: Natera, Inc.: Key Services and Features
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook